Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Left atrial appendage occlusion (LAAO) provides mechanical cardioembolic protection for atrial fibrillation (AF) patients who cannot use oral anticoagulation therapy (OAT). Patients with a thrombotic event despite OAT are at high risk for recurrence and may also benefit from LAAO.
Objectives: This study sought to investigate the efficacy of LAAO in AF patients with a thrombotic event on OAT compared to: 1) LAAO in AF patients with a contraindication for OAT; and 2) historical data.
Methods: The international LAAO after stroke despite oral anticoagulation (STR-OAC LAAO) collaboration included patients who underwent LAAO because of thrombotic events on OAT. This cohort underwent propensity score matching and was compared to the EWOLUTION (Evaluating Real-Life Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology) registry, which represents patients who underwent LAAO because of OAT contraindications. The primary outcome was ischemic stroke. Event rates were compared between cohorts and with historical data without OAT, yielding relative risk reductions based on risk scores.
Results: Analysis of 438 matched pairs revealed no significant difference in the ischemic stroke rate between the STR-OAC LAAO and EWOLUTION cohorts (2.5% vs 1.9%; HR: 1.37; 95% CI: 0.72-2.61). STR-OAC LAAO patients exhibited a higher thromboembolic risk (HR: 1.71; 95% CI: 1.04-2.83) but lower bleeding risk (HR: 0.39; 95% CI: 0.18-0.88) compared to EWOLUTION patients. The mortality rate was slightly higher in EWOLUTION (4.3% vs 6.9%; log-rank P = 0.028). Relative risk reductions for ischemic stroke were 70% and 78% in STR-OAC LAAO and EWOLUTION, respectively, compared to historical data without OAT.
Conclusions: LAAO in patients with a thrombotic event on OAT demonstrated comparable stroke rates to the OAT contraindicated population in EWOLUTION. The thromboembolic event rate was higher and the bleeding rate lower, reflecting the intrinsically different risk profile of both populations. Until randomized trials are available, LAAO may be considered in patients with an ischemic event on OAT.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcin.2024.04.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Left Atrial Appendage Occlusion Devices Focused on Complications of Therapy.
Cardiol Rev
September 2025
Departments of Cardiology and Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY.
Left atrial appendage occlusion (LAAO) is an alternative to oral anticoagulation for stroke prevention in atrial fibrillation (AF), especially in patients at high bleeding risk. While generally safe, LAAO involves procedural and postprocedural risks. The most serious complication is pericardial effusion or tamponade; other periprocedural risks include stroke, device embolization, vascular injury, major bleeding, and air embolism.
View Article and Find Full Text PDFLeft atrial appendage closure in patients with prior intracranial bleeding, safety, efficacy, and timing.
Neurologia (Engl Ed)
September 2025
Hospital Universitario de Salamanca, CIBERCV, IBSAL, Spain.
Background: Oral anticoagulation (OAC) use increases the risk of intracranial hemorrhage (ICH) in patients with atrial fibrillation (AF) and CHADS-VASc ≥2. Left atrial appendage occlusion (LAAO) is an alternative to OAC, however data about its use in patients with prior ICH is scarce and the timing of its performance is controversial. Furthermore, the long-term outcomes in this group of patients have not been described previously.
View Article and Find Full Text PDFMitral valve repair in a dog with a modified taut-line hitch knot technique.
Vet Surg
September 2025
Department of Small Animal Cardiovascular Surgery, Izmir Animal Hospital, Izmir, Turkey.
Objective: To report the outcome of a dog with severe mitral regurgitation (MR) treated with open-heart surgery using the modified taut-line hitch (modified TLH) knot technique.
Methods: A 9-year-old, 8.8-kg intact male Cavalier King Charles Spaniel was referred for clinical signs of congestive heart failure secondary to severe mitral regurgitation.
Age-specific outcomes after transcatheter left atrial appendage occlusion with the watchman device.
J Geriatr Cardiol
July 2025
Structural Heart and Interventional Cardiology, University of Arizona School of Medicine, DHMG Cardiology- Chandler, Chandler, USA.
Background: Transcatheter left atrial appendage occlusion (LAAO) has become a suitable alternative to anticoagulation in patients with atrial fibrillation (AF). However, outcomes among patients age > 75 years undergoing LAAO are lacking.
Methods: We included 723 consecutive patients with AF undergoing LAAO from August 2015 to March 2020.
Left atrial appendage occlusion: real world observational data on in-hospital results, clinical outcome and hemoglobin level.
Scand Cardiovasc J
December 2025
Department of Internal Medicine, Division of Cardiology, Jena University Hospital, Friedrich-Schiller-University of Jena, Jena, Germany.
Background: Interventional left atrial appendage occlusion (LAAO) was developed as a treatment option for patients who cannot receive traditional anticoagulation therapies. To date, randomized study data on this treatment are still limited, so registries and other non-randomized studies may help define the role of LAAO in clinical practice.
Design: We performed LAAO consecutively on 599 patients.